Last reviewed · How we verify

NCT04722770

Clinical Development of Deep Learning for the OtoSight

Completed Last updated 23 January 2024
What this trial tests

trial testing PhotoniCare OtoSight Middle Ear Scope in Otitis Media Acute in 188 participants. Completed in 31 August 2023.

Timeline
19 January 2021
Primary endpoint
2 September 2022
31 August 2023

Quick facts

Lead sponsorPhotoniCare, Inc.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment188
Start date19 January 2021
Primary completion2 September 2022
Estimated completion31 August 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

PhotoniCare, Inc.

Who can join

Adults 6 Months to 4, any sex, with Otitis Media Acute. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to clinically develop and evaluate a machine learning approach to improve the performance and data interpretation of the PhotoniCare OtoSight Middle Ear Scope in pediatric patients presenting at the primary care office for suspected ear infections. In this observational study, results of OtoSight imaging will not affect patient standard of care.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Otitis Media Acute

Currently open trials in the same condition.

Other PhotoniCare, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04722770.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing